Lantern Pharma
LTRN
30 hedge funds and large institutions have $4.95M invested in Lantern Pharma in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 13 reducing their positions, and 0 closing their positions.
400% more call options, than puts
Call options by funds: $10K | Put options by funds: $2K
26% more capital invested
Capital invested by funds: $3.93M → $4.95M (+$1.01M)
11% more funds holding
Funds holding: 27 → 30 (+3)
0.02% more ownership
Funds ownership: 10.62% → 10.63% (+0.02%)
54% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$153K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$41.7K |
| 3 |
Renaissance Technologies
New York
|
+$20.1K |
| 4 |
CM
CM Management
Gulf Breeze,
Florida
|
+$17.6K |
| 5 |
MWM
Meridian Wealth Management
Lexington,
Kentucky
|
+$10.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Carlson Capital
Dallas,
Texas
|
-$123K |
| 2 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
-$22K |
| 3 |
RAM
Redmond Asset Management
Henrico,
Virginia
|
-$20.6K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$20.4K |
| 5 |
PFA
Pathway Financial Advisors
South Burlington,
Vermont
|
-$15.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AF
26
Allworth Financial
Folsom,
California
| $428 | – | – | – |
|
27
JP Morgan Chase
New York
| $56 | +$14 | +4 | +44% |
|
28
Bank of America
Charlotte,
North Carolina
| $21 | +$18 | +5 | New |
|
29
Qube Research & Technologies (QRT)
London,
United Kingdom
| $9 | – | – | – |
|
30
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$71 | -20 | -19% |
|
LTRN Hedge Fund Activity: Q4 2023 in Review
30 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Lantern Pharma (LTRN) for Q4 2023, worth a combined $4.95M — up 26% from $3.93M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new LTRN positions and 0 closed out — a net gain of 3 holders — while 6 added to existing stakes and 13 trimmed.
The largest buyer was Commonwealth Equity Services, adding an estimated $153K. The largest seller was Carlson Capital, cutting an estimated $123K.
- 30 institutional investors held Lantern Pharma (LTRN) as of Q4 2023, up from 27 in Q3 2023.
- Funds reported $4.95M of Lantern Pharma stock for Q4 2023, up 26% quarter-over-quarter.
- 3 funds opened new Lantern Pharma positions in Q4 2023 and 0 closed out, a net change of +3 holders.
- The largest Lantern Pharma buyer in Q4 2023 was Commonwealth Equity Services, an estimated $153K added.
- The largest Lantern Pharma seller in Q4 2023 was Carlson Capital, an estimated $123K sold.
Based on aggregated 13F filings for Q4 2023.